KEYTRUDA

Merck’s KEYNOTE-905 (EV-303) trial showed positive results for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy. The study combined KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) before and after surgery, demonstrating statistically significant and clinically meaningful improvement in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) compared to surgery alone. This represents the first systemic therapy to improve survival in this population, potentially establishing a new standard of care. The treatment’s safety profile was consistent with existing data.

IO Biotech (IOBT) will release topline results from its Phase 3 trial (IOB-013/KN-D18) of Cylembio, an immune-modulatory cancer vaccine, in combination with KEYTRUDA® for advanced melanoma on August 11, 2025. A conference call and live webcast will detail the data comparing Cylembio plus KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment. The trial focuses on patients with unresectable or metastatic melanoma. A replay will be available on the company website.